BRBrooke Rhead

Brooke Rhead

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brooke Rhead has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Genomic Landscape and Treatment Outcomes Associated with CDKN2A/MTAP Loss in Patients with Non–Small Cell Lung Cancer

    by Natalie I. Vokes, Jessica L. Symons, Brooke Rhead, Lingzhi Hong, Pooja A. Shah, Zhongwu Lai, Zhou Zhu, Santiago Treviño, Julian Bryan, Jia Wu, et al.

    Purpose: Homozygous deletion of the 9p21 locus, containing CDKN2A/B and MTAP [CDKN2A/MTAP deletion (CMdel)], underlies emerging therapeutic strategies, including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcome associations of CMdel in non–small cell lung cancer (NSCLC) remain incompletely defined. Experimental Design: We analyzed Tempus Lens records with paired DNA (xT) and RNA (xR) sequencing. After quality filtering (purity ≥40%), 16,947 patients were included in the primary dataset, and 10,996 were included in the validation dataset and stratified by deletion status [CMdel vs. CM wild-type (CMwt)]. IFN status was defined by IFN-kappa (IFNK) expression [log2(TPM + 1)] using the 25th percentile of CMwt as the threshold. Immune composition was inferred by quanTIseq. First-line regimens were grouped as immune checkpoint inhibitor (ICI) monotherapy, ICI chemotherapy, chemotherapy, or tyrosine kinase inhibitors (TKI). Best response and time to next treatment (TTNT) with risk-set adjustment and 18-month truncation were assessed. Results: CMdel occurred in 11.7% (n = 1,991) and 15% (n = 1,676), respectively, and was enriched in mucinous histology, stage IV disease, and never smokers. CMdel was associated with EGFR, TERT, and SMARCA4 alterations, whereas CMwt was associated with RB1, SETD2, and ARID2. More than 50% of CMdel tumors harbored targetable coalterations, enriched in EGFR/ALK/RET and relatively depleted in KRAS. CMdel tumors exhibited lower PD-L1, mutation burden, and immune infiltration. TTNT did not differ by CM status for ICI monotherapy or TKI but was shorter in CMdel for ICI chemotherapy and chemotherapy. Discordant and broad deletions were less common and had weaker TTNT association. IFNK-low expression marked immune-excluded subgroups with worse treatment outcomes. Conclusions: CDKN2A/MTAP loss defines a prevalent, genomically distinct NSCLC subset enriched in actionable drivers. CMdel associates with worse outcomes to ICI/chemotherapy-containing regimens. These findings highlight convergent biology at 9p21 and support biomarker-guided development of PRMT5/MAT2A inhibitors in MTAP-deleted NSCLC.


  • Open Access

    132 Racial differences in TMB measures between paired tumor/normal and tumor-only sequencing across endometrial, bladder, and non-small cell lung cancers

    by Francisco De La Vega, Yannick Pouliot, Chad Reichard, Rotem Ben-Shachar, Brooke Rhead, Kenneth Carson, Matheww Cooney, Kristiyana Kaneva, Afshin Dowlati, Justin Guinney

    Background Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of a tumor, is routinely used as a predictive biomarker for immunotherapy response in metastatic cancer patients. Sequencing of paired tumor and normal specimens allows for correction of TMB estimates with patient-specific germline variants. For tumor only assays, TMB estimates are corrected using germline variant annotations derived from population-scale germline variant surveys. These surveys often underrepresent minorities and individuals of non-European descent, leading to potential inaccuracies in TMB estimates in these populations. Methods Our cohort includes patients who underwent tumor genomic profiling with the Tempus xT Next Generation Sequencing (NGS) assay and diagnosed with non-small cell lung (NSCLC, n=4,583) endometrial (n=3,084), or urothelial (n=2,806) cancer. We used 654 ancestry informative markers selected to overlap the target regions of the 648-gene Tempus xT NGS assay to infer global continental ancestry proportions and imputed race/ethnicity categories using ancestry admixture thresholds. TMB differences in paired sequencing (PS) and tumor-only sequencing (TOS) were evaluated for each imputed race/ethnicity category and cancer type. Statistical comparisons of TMB distributions were assessed using the Kruskall-Wallis test. Results Among the entire cohort, 6,126 patients had PS performed, and 4,347 had TOS performed. The imputed ethnicities were 4% Asian (A), 10% Black (B), 5% Hispanic/Latino (H) and 81% White (W). In NSCLC, median TMB for A, B, H, and W patients was 1.9, 4.2, 3.2, and 3.8 for PS and 4.9, 7.6, 4.9, and 5.4 for TOS. Among endometrial cancers, median TMB for A, B, H, and W patients was 2.1, 2.7, 2.6, and 3.5 for PS and 5.0, 5.4, 5.4, and 5.4 for TOS. Median TMB for A, B, H, and W patients was 3.1, 3.5, 3.5, and 4.2 for PS and 7.3, 6.1, 6.9, and 5.6 for TOS in urothelial cancers. Differences across PS and TOS were significant in each cancer type (pConclusions Paired tumor sequencing reduces estimated TMB compared to tumpor-only sequencing across all racial groups, more significantly for non-White patients.

  • Open Access

    Novel COVID-19 phenotype definitions reveal phenotypically distinct patterns of genetic association and protective effects

    by Genevieve H.L. Roberts, Raghavendran Partha, Brooke Rhead, Spencer C. Knight, Danny S. Park, Marie V. Coignet, Miao Zhang, Nathan Berkowitz, David A. Turrisini, Michael Gaddis, et al.

    INTRODUCTION PARAGRAPH: Multiple large COVID-19 genome-wide association studies (GWAS) have identified reproducible genetic associations indicating that some infection susceptibility and severity risk is heritable. 1-5 Most of these studies ascertained COVID-19 cases in medical clinics and hospitals, which can lead to an overrepresentation of cases with severe outcomes, such as hospitalization, intensive care unit admission, or ventilation. Here, we demonstrate the utility and validity of deep phenotyping with self-reported outcomes in a population with a large proportion of mild and subclinical cases. Using these data, we defined eight different phenotypes related to COVID-19 outcomes: four that align with previously studied COVID-19 definitions and four novel definitions that focus on susceptibility given exposure, mild clinical manifestations, and an aggregate score of symptom severity. We assessed replication of 13 previously identified COVID-19 genetic associations with all eight phenotypes and found distinct patterns of association, most notably related to the chr3/ SLC6A20/LZTFL1 and chr9/ ABO regions. We then performed a discovery GWAS, which suggested some novel phenotypes may better capture protective associations and also identified a novel association in chr11/ GALNT18 that reproduced in two fully independent populations.


  • Open Access

    AncestryDNA COVID-19 Host Genetic Study Identifies Three Novel Loci

    by Genevieve H.L. Roberts, Danny S. Park, Marie V. Coignet, Shannon R. McCurdy, Spencer C. Knight, Raghavendran Partha, Brooke Rhead, Miao Zhang, Nathan Berkowitz, AncestryDNA Science Team, et al.

    Human infection with SARS-CoV-2, the causative agent of COVID-19, leads to a remarkably diverse spectrum of outcomes, ranging from asymptomatic to fatal. Recent reports suggest that both clinical and genetic risk factors may contribute to COVID-19 susceptibility and severity. To investigate genetic risk factors, we collected over 500,000 COVID-19 survey responses between April and May 2020 with accompanying genetic data from the AncestryDNA database. We conducted sex-stratified and meta-analyzed genome-wide association studies (GWAS) for COVID-19 susceptibility (positive nasopharyngeal swab test, n cases =2,407) and severity (hospitalization, n cases =250). The severity GWAS replicated associations with severe COVID-19 near ABO and SLC6A20 ( P P −8 . The strongest association was near IVNS1ABP , a gene involved in influenza virus replication 1 , and was associated only in males. The other two novel loci harbor genes with established roles in viral replication or immunity: SRRM1 and the immunoglobulin lambda locus. We thus present new evidence that host genetic variation likely contributes to COVID-19 outcomes and demonstrate the value of large-scale, self-reported data as a mechanism to rapidly address a health crisis.


  • Open Access

    Global expression and CpG methylation analysis of primary endothelial cells before and after TNFa stimulation reveals gene modules enriched in inflammatory and infectious diseases and associated DMRs

    by Brooke Rhead, Xiaorong Shao, Hong Quach, Poonam Ghai, Lisa F Barcellos, Anne M Bowcock

    Endothelial cells are a primary site of leukocyte recruitment during inflammation. An increase in tumor necrosis factor-alpha (TNFa) levels as a result of infection or some autoimmune diseases can trigger this process. Several autoimmune diseases are now treated with TNFa inhibitors. However, genomic alterations that occur as a result of TNF-mediated inflammation are not well understood. To investigate molecular targets and networks resulting from increased TNFa, we measured DNA methylation and gene expression in 40 human umbilical vein endothelial cell primary cell lines before and 24 hours after stimulation with TNFa via microarray. Weighted gene co-expression network analysis identified 15 gene groups (modules) with similar expression correlation patterns; four modules showed a strong association with TNFa treatment. Genes in the top TNFa-associated module were all up-regulated, had the highest proportion of hypomethylated regions, and were associated with 136 Disease Ontology terms, including autoimmune/inflammatory, infectious and cardiovascular diseases, and cancers. They included chemokines CXCL1, CXCL10 and CXCL8, and genes associated with autoimmune diseases including HLA-C, DDX58, IL4, NFKBIA and TNFAIP3. Cardiovascular and metabolic disease genes, including APOC1, ACLY, ELOVL6, FASN and SCD, were overrepresented in a module that was not associated with TNFa treatment. Of 223 hypomethylated regions identified, several were in promoters of autoimmune disease GWAS loci (ARID5B, CD69, HDAC9, IL7R, TNIP1 and TRAF1). Results reveal specific gene groups acting in concert in endothelial cells, delineate those driven by TNFa, and establish their relationship to DNA methylation changes, which has strong implications for understanding disease etiology and precision medicine approaches.


  • Open Access

    miRNAcontributions to pediatric‐onset multiple sclerosis inferred fromGWAS

    by Brooke Rhead, Xiaorong Shao, Jennifer S. Graves, Tanuja Chitnis, Amy T. Waldman, Timothy Lotze, Teri Schreiner, Anita Belman, Lauren Krupp, Benjamin M. Greenberg, et al.

    Objective: Onset of multiple sclerosis (MS) occurs in childhood for approximately 5% of cases (pediatricMS, or ped‐MS). Epigenetic influences are strongly implicated inMSpathogenesis in adults, including the contribution from microRNAs (miRNAs), small noncodingRNAs that affect gene expression by binding target genemRNAs. Few studies have specifically examined miRNAs in ped‐MS, but individuals developingMSat an early age may carry a relatively high burden of genetic risk factors, and miRNAdysregulation may therefore play a larger role in the development of ped‐MSthan in adult‐onsetMS. This study aimed to look for evidence of miRNAinvolvement in ped‐MSpathogenesis.Methods: GWASresults from 486 ped‐MScases and 1362 controls from the U.S. PediatricMSNetwork and Kaiser Permanente Northern California membership were investigated for miRNA‐specific signals. First, enrichment of miRNA‐target gene network signals was evaluated usingMIGWASsoftware. Second,SNPs in miRNAgenes and in target gene binding sites (miR−SNPs) were tested for association with ped‐MS, and pathway analysis was performed on associated target genes.Results: MIGWASanalysis showed that miRNA‐target gene signals were enriched inGWAS(P = 0.038) and identified 39 candidate biomarker miRNA‐target gene pairs, including immune and neuronal signaling genes. The miR‐SNPanalysis implicated dysregulation of miRNAbinding to target genes in five pathways, mainly involved in immune signaling.Interpretation: Evidence fromGWASsuggests that miRNAs play a role in ped‐MSpathogenesis by affecting immune signaling and other pathways. Candidate biomarker miRNA‐target gene pairs should be further studied for diagnostic, prognostic, and/or therapeutic utility.


  • Open Access

    Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry

    by Calvin Chi, Xiaorong Shao, Brooke Rhead, Edlin Gonzales, Jessica B Smith, Anny H Xiang, Jennifer Graves, Amy Waldman, Timothy Lotze, Teri Schreiner, et al.

    Multiple sclerosis (MS) is an autoimmune disease with high prevalence among populations of northern European ancestry. Past studies have shown that exposure to ultraviolet radiation could explain the difference in MS prevalence across the globe. In this study, we investigate whether the difference in MS prevalence could be explained by European genetic risk factors. We characterized the ancestry of MS-associated alleles using RFMix, a conditional random field parameterized by random forests, to estimate their local ancestry in the largest assembled admixed population to date, with 3,692 African Americans, 4,915 Asian Americans, and 3,777 Hispanics. The majority of MS-associated human leukocyte antigen (HLA) alleles, including the prominent HLA-DRB1*15:01 risk allele, exhibited cosmopolitan ancestry. Ancestry-specific MS-associated HLA alleles were also identified. Analysis of the HLA-DRB1*15:01 risk allele in African Americans revealed that alleles on the European haplotype conferred three times the disease risk compared to those on the African haplotype. Furthermore, we found evidence that the European and African HLA-DRB1*15:01 alleles exhibit single nucleotide polymorphism (SNP) differences in regions encoding the HLA-DRB1 antigen-binding heterodimer. Additional evidence for increased risk of MS conferred by the European haplotype were found for HLA-B*07:02 and HLA-A*03:01 in African Americans. Most of the 200 non-HLA MS SNPs previously established in European populations were not significantly associated with MS in admixed populations, nor were they ancestrally more European in cases compared to controls. Lastly, a genome-wide search of association between European ancestry and MS revealed a region of interest close to the ZNF596 gene on chromosome 8 in Hispanics; cases had a significantly higher proportion of European ancestry compared to controls. In conclusion, our study established that the genetic ancestry of MS-associated alleles is complex and implicated that difference in MS prevalence could be explained by the ancestry of MS-associated alleles. Multiple sclerosis (MS) is an autoimmune disease that is mostly found in populations with northern European ancestry. Our study investigates whether there is evidence that the difference in MS prevalence around the globe could be explained by European MS genetic risk factors in African Americans, Hispanics, or Asian Americans. Our work first established that most alleles associated with MS are not necessarily European, but are in fact, cosmopolitan. However, we also observed in African Americans that European HLA-DRB1*15:01 conferred three times the odds of MS compared to the African allele. The allele HLA-DRB1*15:01 has been shown to be a major genetic risk factor in Europeans and other admixed populations. In addition, we observed genetic variations between European and African HLA-DRB1*15:01 alleles that, based on location, could influence the function of antigen-binding proteins involved in MS. Consequently, it is plausible that ancestry could explain the risk or protective effects of other MS-associated alleles. Additionally, our study found on chromosome 8 in Hispanics a region where MS cases have more European ancestry than controls, implicating there may be new MS risk alleles to be discovered in Hispanics. In conclusion, our study found evidence that the difference in MS prevalence could be explained by European ancestry and established that the ancestry of MS genetic risk factors is complex.


  • Open Access

    Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients

    by Brooke Rhead, Ina S Brorson, Tone Berge, Cameron Adams, Hong Quach, Stine Marit Moen, Pål Berg-Hansen, Elisabeth Gulowsen Celius, Dipen P Sangurdekar, Paola G Bronson, et al.

    DNA methylation is an epigenetic mark that is influenced by environmental factors and is associated with changes to gene expression and phenotypes. It may link environmental exposures to disease etiology or indicate important gene pathways involved in disease pathogenesis. We identified genomic regions that are differentially methylated in T cells of patients with relapsing remitting multiple sclerosis (MS) compared to healthy controls. DNA methylation was assessed at 450,000 genomic sites in CD4+ and CD8+ T cells purified from peripheral blood of 94 women with MS and 94 healthy women, and differentially methylated regions were identified using bumphunter. Differential DNA methylation was observed near four loci: MOG/ZFP57, HLA-DRB1, NINJ2/LOC100049716, and SLFN12. Increased methylation of the first exon of the SLFN12 gene was observed in both T cell subtypes and remained present after restricting analyses to samples from patients who had never been on treatment or had been off treatment for more than 2.5 years. Genes near the regions of differential methylation in T cells were assessed for differential expression in whole blood samples from a separate population of 1,329 women with MS and 97 healthy women. Gene expression of HLA-DRB1, NINJ2, and SLFN12 was observed to be decreased in whole blood in MS patients compared to controls. We conclude that T cells from MS patients display regions of differential DNA methylation compared to controls, and corresponding gene expression differences are observed in whole blood. Two of the genes that showed both methylation and expression differences, NINJ2 and SLFN12, have not previously been implicated in MS. SLFN12 is a particularly compelling target of further research, as this gene is known to be down-regulated during T cell activation and up-regulated by type I interferons (IFNs), which are used to treat MS.


  • Variants within the Leptin Receptor Gene (LEPR) on Chromosome 1p31 Are Associated with MS Susceptibility in a Model Adjusted for Known Disease Risk Factors (P5.275)

    by Anna Barcellos, Milena Gianfrancesco, Xiaorong Shao, Brooke Rhead, Ling Shen, Cathy Schaefer, Lisa Barcellos